- Net Income: 2.55 billion yuan, which is a 9.3% decrease year-on-year (YoY) compared to 2.81 billion yuan.
- Revenue: 41.04 billion yuan, marking a 2.7% increase YoY.
- Analyst Recommendations: 2 buy ratings, 1 hold rating, and 1 sell rating.
- Comparison Basis: Results are compared to values reported in the company’s original disclosures.
A look at Guangzhou Baiyunshan Pharmaceutical Holdings Smart Scores
Factor | Score | Magnitude |
---|---|---|
Value | 5 | |
Dividend | 5 | |
Growth | 4 | |
Resilience | 4 | |
Momentum | 5 | |
OVERALL SMART SCORE | 4.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. is positioned favorably for long-term success with top scores across key factors. According to Smartkarma Smart Scores, the company excels in terms of both value and dividend, indicating strong financial health and potential for steady returns. Furthermore, its robust momentum score suggests positive market sentiment and upward trends in stock performance. With a solid foundation in Chinese patent medicine manufacturing and diversified operations in pharmaceutical products and medical apparatus, Guangzhou Baiyunshan Pharmaceutical Holdings is well-equipped to capitalize on growth opportunities.
Analysts foresee a bright future for Guangzhou Baiyunshan Pharmaceutical Holdings, given its impressive scores in value, dividend, growth, resilience, and momentum. This signifies a well-rounded outlook for the company, highlighting not only its strong financials and shareholder returns but also its capacity for future expansion and market sustainability. As a key player in the Chinese pharmaceutical industry, Guangzhou Baiyunshan Pharmaceutical Holdings stands poised to navigate challenges and capitalize on emerging trends, solidifying its position as a resilient and dynamic market leader.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars